← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Trial (599)Review article (228)Early study (phase 1 or 2) (41)Case reports (176)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (37)

Filter

Publications and studies (1631)

• Commentary or editorialiAn expert's opinion or commentary, not new research. JAK2V617F and ischemic stroke: CHIP or CMD-NBV? (2023/12/12) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape. (2023/12/12) ♡
• Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations. (2023/12/08) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Are transplant indications changing for myelofibrosis? (2023/12/08) ♡
• [Research status and challenges of advanced myeloproliferative neoplasms]. (2023/12/05) ♡
• [Analysis of risk factors for thromboembolism in patients with JAK2(V617F) gene mutation positive myeloproliferative neoplasms]. (2023/12/05) ♡
• [Expression level of Wilms' tumor 1 gene and its correlation with clinical features in patients with myeloproliferative neoplasms]. (2023/12/05) ♡
• [Efficacy and safety of allogeneic hematopoietic stem cell transplantation for the treatment of primary myelofibrosis]. (2023/12/05) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A Case of TAFRO Syndrome Developed after COVID-19 Vaccination. (2023/12/04) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort. (2023/12/01) ♡
• Association of inflammation and abnormal lipid metabolism with risk of thrombosis and thrombosis progression in patients with polycythemia vera: a retrospective study. (2023/12/01) ♡
• Thrombopoietin receptor agonists for refractory thrombocytopenia in patients after autologous hematopoietic stem cell transplantation. (2023/12/01) ♡
• Clinical characteristics and symptom burden of Thai myeloproliferative neoplasm patients. (2023/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Momelotinib: First Approval. (2023/12/01) ♡
• Spectrophotometric Study of Charge-Transfer Complexes of Ruxolitinib with Chloranilic Acid and 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone: An Application to the Development of a Green and High-Throughput Microwell Method for Quantification of Ruxolitinib in Its Pharmaceutical Formulations. (2023/11/30) ♡
• [Evaluation of blood cell morphology with the RBC Advanced Application: Which cut-offs are most needed for which specific abnormalities?]. (2023/11/29) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. MicroRNA in Fibrotic Disorders: A Potential Target for Future Therapeutics. (2023/11/29) ♡
• SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm. (2023/11/27) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib. (2023/11/27) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Acute myocardial infarction in myeloproliferative neoplasms. (2023/11/26) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Aplastic Anemia Mimicking Myelofibrosis: A Diagnostic Dilemma. (2023/11/26) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Complete resolution of primary myelofibrosis in an infant with steroids and hydroxyurea. (2023/11/22) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera. (2023/11/22) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Chronic Myeloproliferative Neoplasms Treatment (PDQ®): Patient Version. (2023/11/17) ♡
• High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis. (2023/11/16) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol. (2023/11/01) ♡
• Evaluation of multiple immunoassay formats for detection of anti-drug antibodies to zinpentraxin alfa. (2023/11/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Is Treatment for Cytopenic Myelofibrosis Still an Unmet Clinical Need? (2023/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms. (2023/11/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. [Characterization of patients with Philadelphia negative myeloproliferative neoplasms and concomitant monoclonal gammopathies: Just coincidence?]. (2023/11/01) ♡
• The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden. (2023/10/31) ♡
• Study of significance of bone marrow microvessel density in myeloproliferative neoplasms in correlation with CD34 blasts, mast cell count and fibrosis. (2023/10/31) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype. (2023/10/29) ♡
• Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials. (2023/10/27) ♡
• Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study. (2023/10/24) ♡
• The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling. (2023/10/24) ♡
• Molecular landscape of the JAK2 gene in chronic myeloproliferative neoplasm patients from the state of Amazonas, Brazil. (2023/10/23) ♡
• Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib-A Real-Life Longitudinal Study. (2023/10/20) ♡
• A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis. (2023/10/17) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: A case of TAFRO syndrome with severe and prolonged thrombocytopenia: diagnostic pitfalls. (2023/10/13) ♡
• Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis. (2023/10/12) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Fibrosis and bone marrow: understanding causation and pathobiology. (2023/10/09) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [A case of prefibrotic primary myelofibrosis in a child with type-Ⅰ CALR gene mutation]. (2023/10/02) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. The tale of two organs: allogeneic hematopoietic stem cell transplantation following liver transplantation in a myelofibrosis patient. (2023/10/01) ♡
• JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms. (2023/09/30) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Leukemic conversion involving RAS mutations of type 1 CALR-mutated primary myelofibrosis in a patient treated for HCV cirrhosis: a case report. (2023/09/29) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms. (2023/09/27) ♡
• Prognostic Significance of the Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) in Patients with Myelofibrosis: A Retrospective Study. (2023/09/24) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Neuropsychiatric disturbance detecting polycythemia vera myelofibrosis: a case report and literature review. (2023/09/22) ♡
• Hairy Cell Leukemia: Hematological and Immunophenotypic Profile of 13 Patients. (2023/09/07) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.